Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AMLCAMBRIDGE, ...
9don MSN
Successfully treated acute myeloid leukemia patients may hold the key to new CAR T cell therapy
Developing effective immunotherapies for acute myeloid leukemia (AML) has long been hampered by a critical challenge: Therapy directed at killing the leukemia cells may also harm the body's ability to ...
CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
The partnership will automate manufacturing of ProT-096, a personalized progenitor T-cell therapy for refractory leukemia and ...
Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: Analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients. This is an ASCO Meeting Abstract from the ...
A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that ...
CAR-T – chimeric antigen receptor T-cell – therapy is a type of immunotherapy specifically developed for each individual patient and involves genetically reprogramming the patient’s own immune system ...
Cancers driven by hiccups in RNA processing can’t hide from our immune system, according to new work published today in Cell. A cross-institutional team Fred Hutch Cancer Center and Memorial Sloan ...
Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan Ther ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results